Rhinxyl

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rhinxyl

Property Description
Active Ingredient Xylometazoline Hydrochloride
Form Nasal Solution (Spray/Drops)
Pharmacological Class Sympathomimetic Agent (Alpha-Adrenoreceptor Agonist)
Common Use Temporary relief of nasal congestion
Origin Synthetic, Imidazoline Derivative

Rhinxyl is a pharmaceutical preparation used for the temporary relief of nasal congestion. It is classified as a topical decongestant and is administered as a single-active-ingredient intranasal solution, typically in the form of drops or a spray. This action is intended to restore comfortable airflow.


What Type of Medicine is Rhinxyl, and What is its Composition?

Rhinxyl contains Xylometazoline Hydrochloride as its sole active ingredient. This compound is chemically defined as a synthetic Imidazoline derivative and is classified pharmacologically as a Sympathomimetic Agent. Xylometazoline is specifically identified as an Alpha-Adrenoreceptor Agonist, which defines its direct mechanism of action. The product is manufactured as an Aqueous Solution, meaning the active substance is dissolved in a water-based liquid vehicle for precise topical delivery to the nasal mucosa.


Rhinxyl's Form and General Purpose as a Topical Decongestant

The presentation of Rhinxyl as an intranasal solution is key to its effect, allowing the medicine to act directly on the affected tissues. The underlying physiological action is local vasoconstriction, or the narrowing of small blood vessels in the nasal lining, which is achieved by stimulating alpha-adrenergic receptors. Xylometazoline's alpha-agonist properties facilitate the reduction of mucosal edema, which is associated with treating obstruction. The medicine works by reducing the physical swelling inside the nose to improve breathing. This restriction of blood flow reduces fluid accumulation and associated mucosal swelling, fulfilling its role as a Decongestant.

What side effects are possible with Rhinxyl?

Possible side effects and safety information

The official safety profile of Rhinxyl (Xylometazoline Hydrochloride) is structured around adverse reactions categorized by frequency and the organ systems affected, as documented in regulatory sources such as the EMA and FDA. Most reported effects are local and are often observed immediately upon application.

Frequency-Classified Adverse Reactions

The majority of side effects are categorized as Common, meaning they may affect up to 1 in 10 people. These frequently reported events include nasal discomfort (such as stinging, burning, or dryness), headache, and nausea. Uncommon effects include epistaxis (nosebleed) and hypersensitivity reactions.

Very Rare effects, or those with a Frequency Not Known (cannot be estimated), are generally linked to systemic absorption, particularly with excessive or prolonged use. These effects may include palpitations, tachycardia (increased heart rate), and increased blood pressure (Hypertension). A key time-related pattern documented in regulatory texts is rebound congestion (Rhinitis medicamentosa), which is officially associated with the prolonged or excessive use of the medicine.

Population-Specific Safety Considerations

The medicine is subject to specific regulatory limitations. It is contraindicated in individuals who have undergone specific surgeries, such as transsphenoidal hypophysectomy. Caution is required in specific populations due to the potential for systemic effects; this includes patients with severe hypertension, cardiac disease (including Long QT syndrome), narrow-angle glaucoma, or hyperthyroidism. Due to the greater risk of systemic absorption and CNS effects, pediatric use requires strictly defined lower concentrations as mandated by regulatory bodies.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory sources document that a Rhinxyl (Xylometazoline Hydrochloride) overdose significantly affects the central nervous system (CNS) and cardiovascular system. The clinical presentation may involve alternating phases of CNS stimulation (restlessness, tremor, agitation) and profound CNS depression (drowsiness, sedation, ataxia, and coma). Critical cardiovascular manifestations are documented, including potentially life-threatening irregularities like severe bradycardia (slowed heart rate), profound hypotension (low blood pressure), and arrhythmias. Other documented physiological signs of overdose include paleness, hypothermia, and respiratory depression.

Required Emergency Action

Regulator-mandated guidance requires that immediate medical attention be sought upon the suspicion of overdose or accidental ingestion. Urgent contact with emergency medical services or a Poison Help Line is specifically required due to the risk of critical systemic events. Accidental ingestion of even small amounts is documented to be highly dangerous in children le 5 years of age, with a risk of severe outcomes including coma and respiratory failure.

Management and Antidote

Management measures listed in official labeling are focused on supportive care, as no specific antidote is known. Officially described procedures include symptomatic and supportive treatment, with potential consideration for administering activated charcoal or atropine for documented severe bradycardia. Hospital observation may be required until systemic effects subside.

Therapeutic Uses of Rhinxyl

What Rhinxyl Treats: Main Uses and Benefits

Rhinxyl, which contains the active ingredient oxymetazoline hydrochloride, is a topical nasal decongestant generally used for short-term symptomatic assistance. The primary therapeutic domain is directed toward addressing symptoms related to physical discomfort in the nasal passages.

It is applied in clinical settings that involve acute or unstable symptom patterns, and is relevant for conditions characterized by periods of heightened symptoms, such as those associated with the common cold, hay fever, and other upper respiratory allergies. Rhinxyl is commonly used to help with symptoms related to systemic imbalance, including nasal congestion and sinus pressure.

It generally contributes to improved comfort during symptomatic periods. The medicine supports patients during episodes of heightened discomfort and assists with maintaining functional stability when symptoms interfere with routine activities.

Common Use: Supportive relief for Nasal Congestion

Regulatory References

  1. NIH MedlinePlus overview of Oxymetazoline Nasal Spray

Eligibility and Restrictions for Use

Rhinxyl (Xylometazoline Hydrochloride) eligibility is strictly defined by regulatory documents, which establish specific conditions and populations that must not use the medicine.

Contraindications and Restrictions

Contraindications (Must Not Use): The medicine is absolutely contraindicated for patients with specific health conditions or concurrent therapies, including:

  • Narrow-Angle Glaucoma
  • Atrophic Rhinitis (Rhinitis Sicca)
  • Recent Transsphenoidal Surgery
  • Concurrent use of Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping MAOIs.
  • Known Hypersensitivity to xylometazoline or excipients.

Conditional Use (Use with Caution): Use is restricted or requires medical supervision for patients with pre-existing conditions such as severe hypertension, Long QT syndrome, hyperthyroidism, diabetes mellitus, prostatic hypertrophy, or pheochromocytoma.

Age-Specific Eligibility

The medicine is generally contraindicated in children under 2 years old. Use in children under 12 is restricted to specific, lower concentrations (0.05%) only, as the adult strength (0.1%) is typically contraindicated for this group. Standard use is permitted for adults and adolescents who do not meet any exclusion criteria.

Pregnancy and Lactation

Rhinxyl is generally not recommended for use during pregnancy or lactation (breastfeeding), as officially documented information recommends caution due to potential systemic effects.

What should I know about interactions with other medicines?

Rhinxyl Interactions with other medicines and products

The official regulatory profile for Rhinxyl (Xylometazoline Hydrochloride) is strictly defined by pharmacodynamic interactions, primarily involving agents that affect the sympathetic nervous system. Regulatory authorities classify co-administration with specific drug classes as contraindicated combinations.

Contraindicated Combinations

The co-administration of Rhinxyl is formally prohibited with the following classes of systemic medicines, as classified in official government documentation:

Class Documented Interaction Outcome
Monoamine Oxidase Inhibitors (MAOIs) Contraindication due to the potential for enhanced systemic effects and precipitating a hypertensive crisis.
Tricyclic Antidepressants (TCAs) Contraindication due to the documented increased risk of cardiovascular events, including hypertension and cardiac arrhythmia.

Other Documented Interactions

The official profile notes that combining Rhinxyl with other sympathomimetic agents may lead to additive cardiovascular effects, resulting in an increased risk of elevated blood pressure and cardiac irregularities. This interaction is rooted in augmented alpha-adrenergic stimulation.

Pharmacokinetic and Substance Interactions

The regulatory label notes that due to the topical administration and limited systemic absorption, no clinically significant pharmacokinetic interactions (such as those mediated by CYP enzymes or transporters) are documented with systemic medicines. The official prescribing information also does not specify mandatory timing separation rules or documented interactions with food, alcohol, or herbal products.

Mechanism of Action

Targeting Alpha-Adrenergic Receptors to Modulate Vascular Tone

Rhinxyl (Xylometazoline) functions as a direct agonist primarily targeting Alpha-1 (alpha1) adrenergic receptors on the smooth muscle cells of the nasal lining. This interaction initiates a specialized G-protein signaling cascade within the cells, which is the mechanism used to modulate local vascular tone. This interaction is the initiating step that triggers the intracellular and subsequent physiological cascade.


Mechanistic Cascade: Vasoconstriction and Extravascular Fluid Reduction

The activation of alpha1 receptors leads to a swift increase in intracellular calcium ( Ca^2+), causing the arterioles and venules to contract (vasoconstriction). This physical narrowing drastically reduces the local blood pressure and flow, specifically lowering the capillary hydrostatic pressure. The reduction in pressure restricts the leakage of plasma fluid (filtration) into the surrounding tissue, leading to a reduction in extravascular fluid volume and associated mucosal edema.


Mechanism Constraint: Receptor Desensitization

The drug's mechanism is subject to a built-in regulatory constraint known as tachyphylaxis or receptor desensitization upon prolonged use. Sustained activation causes alpha-receptors to become unresponsive or down-regulate, which limits the drug's effectiveness. When this constraint is engaged, the loss of vasoconstrictive tone leads to a compensatory reactive vasodilation, causing the mucosal tissue to swell excessively once the drug effect dissipates, counteracting the initial physiological action.

Dosage and Administration Information

How Rhinxyl is Used

Rhinxyl, containing Xylometazoline Hydrochloride, is strictly administered via the intranasal route, applied topically to the lining of the nose as a solution. Standard administration parameters define its use as intermittent and short-term, with specific dosing parameters that must be adhered to.


Dosing and Administration Schedules

Administration frequency is constrained to a minimum interval of 8 to 12 hours between applications, and the total use is capped at a maximum of three applications daily into each nostril. Dosing is tiered by age and solution strength:

  • Adults and Children 12 years and over: Use the 0.1% strength, typically 1 to 3 sprays or 2 to 3 drops in each nostril.
  • Children 6 to 11 years: Use the lower 0.05% strength, with a reduced dose of 1 to 2 sprays or drops in each nostril.

The duration of use is typically limited to 3 to 7 consecutive days, depending on the specific region, to maintain appropriate use patterns. An interval of several days without the product is required if the course duration limit is exceeded.


Key Procedural Requirements

To ensure proper application, it is standard practice to clear the nasal passages (e.g., by gently blowing the nose) immediately prior to use. The last dose of the day is often recommended for use before retiring to bed. Furthermore, each Rhinxyl container is restricted to single-person use only for hygienic reasons. The recommended dose must not be exceeded under any circumstances.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Non-Steroidal Anti-Inflammatory Drug (NSAID) - Selective COX-2 Inhibitor

Research has explored the potential role in several key areas related to pain management and inflammation. Studies evaluated whether its use could be associated with changes in both acute and chronic pain by examining the inhibition of the COX-2 enzyme. Whether this finding affects pain perception is a subject of ongoing study.

Studies have been conducted to evaluate whether taking the drug at the lowest dose explores outcomes related to dose-response relationships. Research has typically evaluated doses up to 200 mg per day in adult participants.


Core Clinical Evidence

Osteoarthritis Pain

Clinical trials compared the drug against placebo in participants with osteoarthritis pain. Research examined the time to potential effect, with some findings suggesting possible effect onset within 30 minutes, when compared to standard NSAIDs.

Rheumatoid Arthritis

For rheumatoid arthritis, studies investigated whether the drug affected joint stiffness and swelling, and explored its interaction with inflammatory mediators. Studies evaluated the effect on patient-reported quality of life measures.

Acute Post-Operative Pain

Research has also investigated the drug’s role in managing pain following surgical procedures. Studies examined the potential for concurrent use with opioid analgesics in a controlled post-operative setting. The combined data from trials assessed evidence related to long-term exposure.


Study Focus on Risk and Excluded Populations

Trial focus has consistently included adverse events related to the gastrointestinal (GI) and cardiovascular (CV) systems. Studies have consistently noted that participants with a history of heart disease were often excluded from trials due to potential cardiovascular risk. Ongoing research examines the GI outcomes in comparison to non-selective NSAIDs.

Key Studies & References

  1. American College of Rheumatology Guideline for the Management of Osteoarthritis

Frequently Asked Questions (FAQ)

Common questions about Rhinxyl (FAQ)

Q: Why do some people say Rhinxyl helps with allergy symptoms?

Official information indicates that Xylometazoline, the active ingredient in Rhinxyl, is used for the temporary relief of nasal congestion. This type of congestion can be associated with various causes, including the common cold, hay fever, or other respiratory allergies. The medicine's action focuses on reducing swelling in the nasal passages, which addresses the physical obstruction often associated with congestion.

Q: How quickly should I expect to feel a difference after starting Rhinxyl?

Regulatory documents suggest that the decongestant effect of Rhinxyl can typically begin quite quickly, sometimes within just a few minutes, such as 5 to 10 minutes after application. The full effect, or peak relief, has been noted in some studies to take around 30 minutes to become noticeable.

Q: How long does the effect of one use of Rhinxyl typically last?

The effect's duration, typically up to 10 hours, is consistent with the product's official dosing interval, which is every 8 to 12 hours. This information is derived from official product guidance.

Q: Is it normal to not feel the effect of Rhinxyl immediately?

While the medicine's action often begins quickly, it is consistent with product information that the full effects may take up to 30 minutes to develop, even though initial action may begin earlier. This means a person may not feel the full benefit immediately after use.

Q: Does Rhinxyl affect sleep patterns or energy levels?

Official information lists trouble sleeping (insomnia) as a possible side effect of the medicine. Separately, studies have explored whether relieving nasal congestion with the product is associated with improvements in factors like sleep quality and vitality/energy levels.

Q: Does Rhinxyl have any known effects on my ability to drive or operate machinery?

Product information and regulatory summaries state that this medicine is generally not expected to affect a person's ability to drive or operate machinery. This information should be reviewed in conjunction with all known side effects.

Q: Is Rhinxyl available over-the-counter in some countries?

The active ingredient, Xylometazoline, is widely recognized as an established nasal decongestant. Official sources indicate that this compound is commonly available as an over-the-counter (OTC) nasal spray or drops in many countries and regions globally.

Q: Can Rhinxyl be used alongside other allergy medications, like antihistamines?

The official interaction profile strictly warns against co-administration with medicines that intensify sympathetic nervous system activity, such as MAOIs. While no major interactions are generally noted with non-sympathomimetic allergy medicines like antihistamines, consulting with a healthcare provider remains the best source of guidance regarding specific combinations.

Q: Can people with kidney or liver issues use Rhinxyl?

Due to potential systemic considerations, official guidance suggests that patients with pre-existing conditions affecting the kidney or liver should consult a healthcare provider before using this product. Determining the medicine's suitability requires individual assessment and medical supervision.

Q: If I miss a dose of Rhinxyl, what are the general guidelines for what to do?

General guidelines for this type of medication state that a person should use it as soon as they remember if a dose is missed. However, if it is almost time for the next scheduled application, general guidelines indicate that a person should skip that dose to avoid using doses too closely together. It is not advised to use double the amount.

Q: Is Rhinxyl a controlled substance?

Based on regulatory status checks, Xylometazoline, the active ingredient in Rhinxyl, is not classified as a controlled drug or controlled substance by regulatory bodies.

Q: What are common patient expectations regarding the full effect of Rhinxyl?

Clinical studies often assess the drug's effect using patient-reported data. This data suggests that the relief provided by the medicine has been associated with improvements in quality of life factors, including physical symptoms and the ability to engage in daily social activities.

Q: What should I do if I suspect an interaction between Rhinxyl and another medicine?

Official safety protocols advise that if a serious adverse reaction or interaction is suspected, a person should stop using the product immediately. They should then contact their healthcare provider or emergency services.

Q: Is it true that Rhinxyl has less systemic absorption than older medicines in this class?

Regulatory documents confirm that due to its topical, intranasal route of administration, Rhinxyl is associated with limited systemic absorption, which is a documented characteristic of the drug. Its systemic absorption is not directly compared to older medicines in the product label.

Q: What happens if a person stops using Rhinxyl suddenly?

Rebound congestion is a condition associated with prolonged or excessive use of the product. When use is stopped, the underlying issue—the congestion—may return, or the mucosal tissue may swell excessively for a period.

Q: Does Rhinxyl interact with supplements like St. John's Wort or fish oil?

The official interaction profile does not list any mandatory timing separation rules or documented interactions with food, alcohol, or herbal products, including commonly used supplements. Given the warnings regarding sympathomimetic agents, consulting with a healthcare professional remains the official guidance.

Q: Does the time of day I use Rhinxyl matter for its effectiveness?

While the medicine works at any time of day, product use guidelines suggest that the last dose of the day is often recommended for use before retiring to bed. This timing consideration is noted to support clear nasal passages during the night.

Q: How does Rhinxyl fit into the overall treatment plan for the condition it treats?

Rhinxyl is classified as a topical decongestant. Its defined use as short-term and intermittent indicates it is intended for rapid, symptomatic relief of congestion rather than long-term management of chronic conditions.

Q: What are the chances of experiencing a major side effect from Rhinxyl?

Official safety data categorizes adverse reactions by frequency, ranging from Common (up to 1 in 10 people) to Very Rare or Frequency Not Known. Serious systemic effects, such as increased blood pressure or irregular heart rate, are generally categorized in the Very Rare or Not Known frequency brackets in official documentation.

How should Rhinxyl be stored and disposed of?

How to Store and Dispose of Rhinxyl?

This information is based on standard regulatory requirements for storing and disposing of medicinal products.

Storage Requirements

Condition Requirement (Official Statement)
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep the medicine in its original container to protect it from light and moisture.
Prohibited Do not freeze. Freezing may compromise the product's stability and effectiveness.
Child Safety Keep Rhinxyl out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Rhinxyl must be disposed of according to official regulatory guidelines to prevent environmental contamination and accidental ingestion.

Do not flush the medicine down a toilet or pour it into a drain unless specifically instructed by official waste programs. The appropriate method is typically to return the product to an authorized pharmaceutical take-back scheme or collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rhinxyl found in:

A-Z Index: